MENU
+Compare
IMAB
Stock ticker: NASDAQ
AS OF
Jun 6 closing price
Price
$2.45
Change
+$0.16 (+6.99%)
Capitalization
186.19M

IMAB I-MAB Forecast, Technical & Fundamental Analysis

I-MAB is a clinical-stage biotech company... Show more

IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IMAB with price predictions
May 28, 2025

IMAB in upward trend: price rose above 50-day moving average on April 30, 2025

IMAB moved above its 50-day moving average on April 30, 2025 date and that indicates a change from a downward trend to an upward trend. In of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on IMAB as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for IMAB crossed bullishly above the 50-day moving average on April 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMAB advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 82 cases where IMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMAB broke above its upper Bollinger Band on May 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.939) is normal, around the industry mean (16.080). P/E Ratio (0.000) is within average values for comparable stocks, (59.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.197). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (16.978) is also within normal values, averaging (268.270).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

IMAB is expected to report earnings to rise 539.50% to -12 cents per share on November 29

I-MAB IMAB Stock Earnings Reports
Q3'23
Est.
$-0.13
Q1'25
Beat
by $0.09
Q4'24
Est.
$-0.06
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.22
The last earnings report on May 15 showed earnings per share of -1 cents, beating the estimate of -10 cents. With 3.35M shares outstanding, the current market capitalization sits at 186.19M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
555 West Haiyang Road
Phone
+86 2160578000
Employees
318
Web
https://www.i-mabbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

IMAB and Stocks

Correlation & Price change

A.I.dvisor tells us that IMAB and RPRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMAB and RPRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
+12.50%
RPRX - IMAB
31%
Poorly correlated
-0.18%
IRD - IMAB
31%
Poorly correlated
-1.47%
TPST - IMAB
28%
Poorly correlated
+1.94%
LGND - IMAB
27%
Poorly correlated
-1.43%
UBX - IMAB
26%
Poorly correlated
-7.71%
More